Bioorganic
264 papers17 directions
Bioorganic is a research venue that has been active since 1991, with a collection of 263 papers documented through 2026. The venue focuses on the intersection of chemical biology and drug discovery, providing a platform for research into the design, synthesis, and biological evaluation of small molecules. Its scope encompasses a variety of therapeutic areas, including oncology, immunology, and antifungal treatments. Prolific contributors to the venue include researchers such as Thierry Langer, Andreas Verras, and Dong‐Ming Shen.
The research published at Bioorganic frequently centers on the identification of potent inhibitors and the development of novel molecular scaffolds. Sample studies include the discovery of mTOR inhibitors for acute myeloid leukemia, URAT1 inhibitors with hypouricemic effects, and the design of PD-L1-targeted molecules for cancer therapy. The venue also features work on molecular glue degraders and natural product-inspired derivatives, reflecting a focus on diverse chemical strategies for modulating biological targets.
In the context of machine learning and computational research, Bioorganic serves as a site for the application of molecular design technologies and structural analysis. The venue documents the use of emerging insights in immunomodulatory technologies and the identification of selective inhibitors, such as those targeting ROCK2 or tubulin polymerization. By publishing detailed findings on structure-activity relationships and oral bioavailability, the venue contributes to the data and methodologies used in the computational screening and optimization of therapeutic candidates.
Papers by Year
Top Research Directions
Research directions most represented by papers from this venue.
Top Authors
Impactful Papers
Papers from this venue that shaped research clusters.
Foundational
Influential
Related Venues
Venues with the most similar research cluster distributions.
Papers
| Title | Year |
|---|
| Antibacterial activity of ruthenium(II) polypyridyl complex manipulated by membrane permeability and cell morphology | 2015 |
| Anti-plasmodial activity of bradykinin and analogs | 2015 |
| A triphenylamine-based colorimetric and fluorescent probe with donor–bridge–acceptor structure for detection of G-quadruplex DNA | 2015 |
| C-Aryl glucoside SGLT2 inhibitors containing a biphenyl motif as potential anti-diabetic agents | 2015 |
| Design and synthesis of a crosslinker for studying intracellular steroid trafficking pathways | 2015 |
| Design, synthesis and docking study of novel tetracyclic oxindole derivatives as α-glucosidase inhibitors | 2015 |
| Development of novel adenosine receptor ligands based on the 3-amidocoumarin scaffold | 2015 |
| Discovery of LRRK2 inhibitors using sequential in silico joint pharmacophore space (JPS) and ensemble docking | 2015 |
| Insights into the interaction of negative allosteric modulators with the metabotropic glutamate receptor 5: Discovery and computational modeling of a new series of ligands with nanomolar affinity | 2015 |
| Modular synthesis and biological activity of pyridyl-based analogs of the potent Class I Histone Deacetylase Inhibitor Largazole | 2015 |
| Synthesis and bioactivity of tripolinolate A from Tripolium vulgare and its analogs | 2015 |
| Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3 | 2015 |
| A comparative study of trans- and cis-isomers of a bone-seeking agent, DO2A2P | 2014 |
| Corrigendum to “Anthraquinone derivatives from Rumex plants and endophytic Aspergillus fumigatus and their effects on diabetic nephropathy” [Bioorg. Med. Chem. Lett. 23 (2013) 3905–3909] | 2014 |
| Design, synthesis, and biological evaluation of novel 2-methylpiperazine derivatives as potent CCR5 antagonists | 2014 |
| Design, synthesis and in vitro pharmacology of GluK1 and GluK3 antagonists. Studies towards the design of subtype-selective antagonists through 2-carboxyethyl-phenylalanines with substituents interact | 2014 |
| Discovery of potent and selective GIRK1/2 modulators via ‘molecular switches’ within a series of 1-(3-cyclopropyl-1-phenyl-1H-pyrazol-5-yl)ureas | 2014 |
| Molecular modeling studies of atorvastatin analogues as HMGR inhibitors using 3D-QSAR, molecular docking and molecular dynamics simulations | 2014 |
| Potent and selective MAO-B inhibitory activity: Amino- versus nitro-3-arylcoumarin derivatives | 2014 |
| Structure-based design of novel human Pin1 inhibitors (III): Optimizing affinity beyond the phosphate recognition pocket | 2014 |
| Synthesis and antiproliferative evaluation of 2-hydroxylated (E)-stilbenes | 2014 |
| Synthesis and biological evaluation of a novel class of coumarin derivatives | 2014 |
| 2-Amino-[1,2,4]triazolo[1,5-a]pyridines as JAK2 inhibitors | 2013 |
| Development of carbamate-tethered coumarins as phototriggers for caged nicotinamide | 2013 |
| Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitors | 2013 |
| Exploration of the 5-bromopyrimidin-4(3H)-ones as potent inhibitors of PDE5 | 2013 |
| New eudesmane sesquiterpenes from Alpinia oxyphylla and determination of their inhibitory effects on microglia | 2013 |
| Oxazolopyridines and thiazolopyridines as monoamine oxidase B inhibitors for the treatment of Parkinson’s disease | 2013 |
| Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA | 2013 |
| Synthesis and biological evaluation of novel benzyl-substituted (S)-phenylalanine derivatives as potent dipeptidyl peptidase 4 inhibitors | 2013 |
| Synthesis and HDAC inhibitory activity of isosteric thiazoline-oxazole largazole analogs | 2013 |
| Synthesis and photochemical behavior of coumarin-caged cholesterol | 2013 |
| The effect of the skeleton structure of flavanone and flavonoid on interaction with transferrin | 2013 |
| 2-(4-Chlorophenyl)-2-oxoethyl 4-benzamidobenzoate derivatives, a novel class of SENP1 inhibitors: Virtual screening, synthesis and biological evaluation | 2012 |
| A new class of prolylcarboxypeptidase inhibitors, Part 1: Discovery and evaluation | 2012 |
| A new class of prolylcarboxypeptidase inhibitors, Part 2: The aminocyclopentanes | 2012 |
| Biodegradable cyclen-based linear and cross-linked polymers as non-viral gene vectors | 2012 |
| Design, synthesis, and biological activity of novel 1,4-disubstituted piperidine/piperazine derivatives as CCR5 antagonist-based HIV-1 entry inhibitors | 2012 |
| Discovery of aminoheterocycles as potent and brain penetrant prolylcarboxypeptidase inhibitors | 2012 |
| Discovery of benzodihydroisofurans as novel, potent, bioavailable and brain-penetrant prolylcarboxypeptidase inhibitors | 2012 |
| Phthalazinone inhibitors of inosine-5′-monophosphate dehydrogenase from Cryptosporidium parvum | 2012 |
| Radiosynthesis of PET radiotracer as a prodrug for imaging group II metabotropic glutamate receptors in vivo | 2012 |
| Structure–activity relationship study of selective benzimidazole-based inhibitors of Cryptosporidium parvum IMPDH | 2012 |
| Structure-guided design, synthesis and biological evaluation of novel DNA ligase inhibitors with in vitro and in vivo anti-staphylococcal activity | 2012 |
| Diabetic nephropathy-related active cyclic peptides from the roots of Brachystemma calycinum | 2011 |
| Dimerization of piceatannol by Momordica charantia peroxidase and α-glucosidase inhibitory activity of the biotransformation products | 2011 |
| Discovery of a new class of potent prolylcarboxypeptidase inhibitors derived from alanine | 2011 |
| Discovery of benzimidazole pyrrolidinyl amides as prolylcarboxypeptidase inhibitors | 2011 |
| The discovery of non-benzimidazole and brain-penetrant prolylcarboxypeptidase inhibitors | 2011 |
| Corrigendum to “Deconstructing estradiol: Removal of B-ring generates compounds which are potent and subtype-selective estrogen receptor agonists” [Bioorg. Med. Chem. Lett. 19 (2009) 1250] | 2010 |
« prev Page 4/6 next »